	DEPARTMENT OF HEAD	TH AND HUMAN S G ADMINISTRATION	SERVICES	
DISTRICT ADDRESS AND PHONE		GADMINISTRATION	DATE(S) OF INSPECTION	
1431 Harbor B		08/25/2015 - 09/16/	2015*	
Alameda, CA (510) 337-670	94502-7070 0 Fax:(510) 337-6702	3010479366		
Industry Info	ndustry Information: www.fda.gov/oc/industry			
<ul> <li>South the same of the first of the same o</li></ul>	TO WHOM REPORT ISSUED  h A. Holmes, Chief Executive		i Founder	25 Mer 17 19 19 19 19 19 19 19 19 19 19 19 19 19
FIRM NAME		STREET ADDRESS		
Theranos, Inc	nc. 1701 Page		TILI KOAQ	
Palo Alto, CA	94304-1111	Manufacture	r	
observations, and do no observation, or have in action with the FDA n	bservations made by the FDA representative(s) not represent a final Agency determination regamplemented, or plan to implement, corrective representative(s) during the inspection or submact FDA at the phone number and address about	arding your compliant action in response to it this information to	nce. If you have an objection rega o an observation, you may discuss	rding an the objection or
	oted in this Form FDA-483 are not an exh for conducting internal self-audits to iden			
DURING AN INSPEC	TION OF YOUR FIRM WE OBSERVED:			U1945-1011
OBSERVATION	1			
OBSERVATION				
Design validation d	lid not ensure the device conforms to defin	ed user needs and	l intended uses.	i (In
Specifically,				
You provided (b) (			20.0	vidence of
design validation w	hich was conducted in April 2014. The va	lidation:	as c	TIMORIOU UI
715) 743	The second section of the second seco			
(9) (4)				
(b) (4)				
	EMPLOYEE(S) SIGNATURE	A		DATE ISSUED
SEE REVERSE OF THIS PAGE	Seema S. Singh, Investigate Ian A. Pilcher, Investigate	or h		09/16/2015
FORM FDA 483 (69/68)	PREVIOUS EDITION OBSOLETE INSP	ECTIONAL OBSER	VATIONS	PAGE 1 OF 4 PAGES

		LTH AND HUMAN SERVICES UG ADMINISTRATION	
1431 Harbor B Alameda, CA (510) 337-670	enumber Bay Parkway	DATE(S) OF INSPECTION  08/25/2015 - 09/1  FEI NUMBER  3010479366	16/2015*
	rmation: www.fda.gov/oc/indu		
	th A. Holmes, Chief Executive		
Theranos, Inc	<b>9</b>	1701 Page Mill Road	
Palo Alto, CA		Manufacturer	
Specifically, Your design valida (b) (2) (b) (4) prov. (b) (4) and equipment that specific instrument	tion plan (13) (21)  ided as evidence of design validation, does that were produced using the same special will be used for routine production. For each or analyzers used, documents with revision.	s not demonstrate that TSCD (b) (4) ifications, production and (b) (4) example, you do not list or refer to the TSCD	procedures, lot numbers used, ocols used.
OBSERVATION  Design input requir	rements were not adequately documented.		360
Specifically,			
B. You (5) (4) ith	ner a (b) (d)  n your design requirement of the (b) (d)	Revision A, you list the list (a) (b) (c) (d) (d) (e) to collect patient samples and have reported to your TSCD device. You do not address or specifications document such that the collect patient samples and have reported to collect patient sampl	for each the results with at ess the amount of device will perform
OBSERVATION	4		
Results of the desig	gn risk analysis were not adequately docu	mented.	
Specifically,			
g 18 <b>3</b> 0	nultiple assay results to patients using the	TSCD devices (b) (4)	
provido il	EMPLOYEE(S) SIGNATURE		DATE ISSUED
SEE REVERSE OF THIS PAGE	Seema S. Singh, Investigate Ian A. Pilcher, Investigate		09/16/2015
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INSI	ECTIONAL OBSERVATIONS	PAGE 2 OF 4 PAGES

	DEPARTMENT OF HEALTH AND HUMAN SERVICES								
DISTRICT ADDRESS AND PHONE NUMBER FOOD AND DRUG ADMINISTRATION			DATE(S) OF INSPECTION						
1431 Harbor E		08/25/2015 - 09/16/	/2015*						
	Alameda, CA 94502-7070 (510) 337-6700 Fax:(510) 337-6702		3010479366						
Industry Info	ormation: www.fda.gov/oc/indu	stry							
	th A. Holmes, Chief Executive		i Founder						
	Theranos, Inc. 1701 Page		Mill Road						
Palo Alto, CA		TYPEESTABUSHMENT INSPECTED  Manufacturer							
However, you do not document the possible hazards associated with the TSCD design for the ISCD design for									
( <b>b</b> ) ( <b>4</b> )									
ine) feri									
	3								
OBSERVATION 5									
Documents were not reviewed and not approved by designated individual(s) prior to issuance.									
Specifically,									
A. (b) (4) DOC-0069 Revision A, provided as the hazard analysis for the levices, was utilized from February-April 2014. The document does not have an effective date. The document was not released in your document control system until 8/26/15 (during the inspection). The document was not reviewed and approved prior to 8/26/15.									
B. There is no do	ocument number, revision or effective date	for your design v	alidation (b) (4)						
These documents were provided as evidence of design validation conducted in 2014; however, they were drafted during this inspection and were not reviewed and approved until 9/10/15.									
C. There is no do	ocument number, revision or effective date								
conducted in 2 9/10/15.	This document was pr 2014; however, this document was drafted		r-up to the failures in your desi ion. It has not been reviewed o						
	EMPLOYEE(S) SIGNATURE	2001 00 040		DATE ISSUED					
SEE REVERSE OF THIS PAGE	Seema S. Singh, Investigate Ian A. Pilcher, Investigate	or All		09/16/2015					
	J		The second second						

INSPECTIONAL OBSERVATIONS

PAGE 3 OF 4 PAGES

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER DATE(S) OF INSPECTION 1431 Harbor Bay Parkway 08/25/2015 - 09/16/2015\* FEI NUMBER Alameda, CA 94502-7070 (510) 337-6700 Fax: (510) 337-6702 3010479366 Industry Information: www.fda.gov/oc/industry TO: Elizabeth A. Holmes, Chief Executive Officer and Founder FIRM NAME STREET ADDRESS Theranos, Inc. 1701 Page Mill Road Palo Alto, CA 94304-1111 Manufacturer **Observation Annotations** Observation 2: Observation 1: Reported corrected, not verified. Reported corrected, not verified. Observation 3: Reported corrected, not verified. Observation 4: Reported corrected, not verified. Observation 5: Reported corrected, not verified. \* DATES OF INSPECTION: 08/25/2015(Tue), 08/26/2015(Wed), 08/27/2015(Thu), 08/28/2015(Fri), 09/01/2015(Tue), 09/02/2015(Wed), 09/03/2015(Thu), 09/04/2015(Fri), 09/09/2015(Wed), 09/10/2015(Thu), 09/11/2015(Fri), 09/16/2015(Wed)

SEE REVERSE Sees

Seema S. Singh, Investigator \_ Ian A. Pilcher, Investigator

Lli

DATE ISSUED

09/16/2015

EMPLOYEE(S) SIGNATURE